Caligan picks up a stake in Verona Pharma, seeing an opportunity to generate more value

Business: Verona Pharma , a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. This medication is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary di ...